Bausch + Lomb Aktie

Bausch + Lomb has received CE marking for the SeeLyra femtosecond laser system. The system is designed for cataract surgery, creation of LASIK flaps and therapeutic corneal treatments and features integrated swept‑source OCT for real‑time depth visualization. SeeLyra will be available in limited quantities in Europe in the coming months, with broader availability planned for 2027; approvals in additional markets, including the US, are being sought. » More on de.investing.com

At the request of Bausch Health, Bausch + Lomb appointed four new members to its board and had the previous members step down; the appointments include executives and investors. In the second quarter, sales rose to $1.394 billion (reported +9%, currency-adjusted +8%) and operating cash flow increased to $153 million. The company affirmed its raised 2026 revenue guidance of $5.440–5.540 billion and adjusted EBITDA before acquired R&D of $1.025–1.075 billion, and points to an active product pipeline in eye health, surgical technologies, contact lenses, retinal diseases and applications of AI and computational biology. » More on de.investing.com

Bausch + Lomb’s stock climbed 2.3% pre-market after Q2 results: revenue $1.39bn (consensus $1.37bn, +9% YoY), adjusted EPS $0.15 in line with estimates. The company raised its 2026 revenue forecast to $5.44–5.54bn; operating income swung from -$11m to +$83m, operating cash flow rose to $153m and adjusted EBITDA to $241m. UBS initiated coverage with a buy recommendation; investors view the numbers as confirmation of the operational turnaround. » More on de.investing.com